SMAD4 and hepatocellular carcinoma: Although homozygous deletions or intragenic mutations account for up to 60% of the SMAD4 inactivation in pancreatic and colorectal carcinoma, no homozygous deletion and only 6% of intragenic mutations of SMAD4 were detected in HCC [25].